Yoon Jeon Kim1, Kyung Rim Sung1, Kyoung Sub Lee1, Soo Geun Joe1, Joo Yong Lee1, June-Gone Kim1, Young Hee Yoon2. 1. Department of Ophthalmology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, South Korea. 2. Department of Ophthalmology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address: yhyoon@amc.seoul.kr.
Abstract
PURPOSE: To evaluate long-term effects of multiple intravitreal antivascular endothelial growth factor (VEGF) injections on intraocular pressure (IOP) in eyes with neovascular age-related macular degeneration (AMD) or retinal vein occlusion (RVO). DESIGN: Retrospective cohort study. METHODS: This study enrolled patients who underwent multiple (more than 3) intravitreal anti-VEGF injections and who were followed for more than 12 months after their last injection. IOP elevation was defined as an increase of 5 mm Hg over the baseline measurement on 2 consecutive visits. The frequency of IOP elevation was determined. A hazard ratio of each putative risk factor for IOP elevation was calculated using the Cox proportional hazard model for all participants, incorporating underlying disease as a covariate, as well as for each cohort. RESULTS: Included in the analysis were 629 eyes with neovascular AMD and 95 eyes with RVO. Twenty eyes with neovascular AMD (3.0%) and 7 eyes with RVO (7.4%) experienced IOP elevation after multiple anti-VEGF injections, with an overall incidence of 3.7%. In the Cox proportional hazard analysis of total participants, a diagnosis of RVO (3.424, P = 0.005), a history of glaucoma (8.441, P = 0.001), and low baseline IOP (0.865, P = 0.040) were all significant risk factors for IOP elevation after multiple anti-VEGF injections. CONCLUSION: A history of multiple intravitreal anti-VEGF injections was not a significant risk factor for IOP elevation in our study. IOP elevation was more common in eyes with RVO than with AMD after anti-VEGF injection.
PURPOSE: To evaluate long-term effects of multiple intravitreal antivascular endothelial growth factor (VEGF) injections on intraocular pressure (IOP) in eyes with neovascular age-related macular degeneration (AMD) or retinal vein occlusion (RVO). DESIGN: Retrospective cohort study. METHODS: This study enrolled patients who underwent multiple (more than 3) intravitreal anti-VEGF injections and who were followed for more than 12 months after their last injection. IOP elevation was defined as an increase of 5 mm Hg over the baseline measurement on 2 consecutive visits. The frequency of IOP elevation was determined. A hazard ratio of each putative risk factor for IOP elevation was calculated using the Cox proportional hazard model for all participants, incorporating underlying disease as a covariate, as well as for each cohort. RESULTS: Included in the analysis were 629 eyes with neovascular AMD and 95 eyes with RVO. Twenty eyes with neovascular AMD (3.0%) and 7 eyes with RVO (7.4%) experienced IOP elevation after multiple anti-VEGF injections, with an overall incidence of 3.7%. In the Cox proportional hazard analysis of total participants, a diagnosis of RVO (3.424, P = 0.005), a history of glaucoma (8.441, P = 0.001), and low baseline IOP (0.865, P = 0.040) were all significant risk factors for IOP elevation after multiple anti-VEGF injections. CONCLUSION: A history of multiple intravitreal anti-VEGF injections was not a significant risk factor for IOP elevation in our study. IOP elevation was more common in eyes with RVO than with AMD after anti-VEGF injection.
Authors: Joanne C Wen; Ester Reina-Torres; Joseph M Sherwood; Pratap Challa; Katy C Liu; Guorong Li; Jason Y H Chang; Scott W Cousins; Stefanie G Schuman; Priyatham S Mettu; W Daniel Stamer; Darryl R Overby; R Rand Allingham Journal: Invest Ophthalmol Vis Sci Date: 2017-03-01 Impact factor: 4.799
Authors: Alexander J E Foss; Lauren J Scott; Chris A Rogers; Barney C Reeves; Faruque Ghanchi; Jonathan Gibson; Usha Chakravarthy Journal: Br J Ophthalmol Date: 2016-04-12 Impact factor: 4.638